To Start Construction of Plant 5 This Year
Samsung Biologics announced its sustainable growth plan for this year at the 2022 Annual J.P. Morgan Healthcare Conference, which was held virtually from Jan. 10-13 with leaders from major pharmaceutical and biopharmaceutical companies and key investors.
During the main track presentation on Jan. 12 (U.S. local time), John Rim, president and CEO of Samsung Biologics, sketched out the company’s vision for 2022 and business goals including three core pillars of multidimensional growth plan, encompassing expanded manufacturing capacity, continued advancements in business portfolio, and greater global footprint.
“For Samsung Biologics, 2022 will be a year when we will be able to take a great leap forward for sustainable growth and endeavor to maximize our capabilities as a leading CDMO,” Rim said.
As part of its growth plan, Samsung Biologics is planning to start the construction of a new facility, Plant 5 this year, where it will offer multi-modal products including cell & gene therapies and next-gen vaccines utilizing mRNA, pDNA and viral vectors, all at a single site. This will be additional to the mRNA vaccine drug substance (DS) manufacturing suite the company is currently adding to its existing facility in Songdo, which is expected to be ready for cGMP operations within the earlier part of this year.
The company is further venturing into securing additional sites within Songdo for the construction of Plant 6 and Open Innovation Center, and also overseas in multiple locations to maximize both its manufacturing capacity to produce large-scale biologics and be in proximity to its global clients.
Samsung Biologics’ Plant 4 is currently under construction to be partially operational by the end of this year, and the company is steadily securing pre-sales of clients. Upon the full completion of Plant 4 in 2023, the company is expected to hold a total of 620,000L of capacity, reaffirming its position as the world’s largest CDMO.
“The strategic roadmap and milestones outlined today illustrate the key success drivers for our growth this year as well as lay a strong groundwork for sustainable growth opportunities ahead of us,” Rim added. “With our continued investment in capacity, portfolio, and global footprint, we will evolve as the top biopharmaceutical company and offer diversified services as the next growth engine of the industry.”